About 100 reports

  • Clinical Trial profile. 125 Trial Title
  • Clinical Trial Profile Snapshots

Duodenal Ulcer Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* Clinical Trials by G## Countries: Proportion of Duodenal Ulcer to Gastrointestinal Clinical Trials Among the G## (United States, United Kingdom, Germany, France, Italy, Canada and Japan) countries, Ja

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • World
  • Product Initiative
  • Proportion of Traveler's Diarrhea to Gastrointestinal Clinical Trials, G7 Countries (%), 2015*
  • Proportion of Traveler's Diarrhea to Gastrointestinal Clinical Trials, E7 Countries (%), 2015*
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pathology
  • World
  • Product Initiative

The company' s products are used for the treatment of pain management, immunological diseases, and gastrointestinal disorders.

  • Gastrointestinal Drug
  • Opioid
  • Pharmaceutical
  • Therapy
  • World
  • Clinical Trial profile. 336 Trial Title
  • Official Title

Oxycodone in Early Return of Gastrointestinal Function After Colorectal Surgery A Comparison of Targinact vs.

  • Gastrointestinal Drug
  • Hospital
  • Therapy
  • World
  • Product Initiative
  • CHIRONWELLS GMBH

The company' s products are used for the treatment of pain management, immunological diseases, and gastrointestinal disorders.

  • Gastrointestinal Drug
  • Opioid
  • Therapy
  • World
  • Product Initiative
  • Opioid-Induced Constipation (OIC) - Pipeline by Theravance Biopharma Inc, H2 2017
  • Opioid-Induced Constipation (OIC) - Pipeline by Sucampo Pharmaceuticals Inc, H2 2017

These medicines affect the gastrointestinal tract in a variety of ways.

  • Gastrointestinal Drug
  • Opioid
  • United States
  • World
  • Product Initiative
  • 05/24/2016: EVOKE PHARMA PRESENTS DATA FROM SUCCESSFUL THOROUGH ECG (TQT) STUDY OF EVK-001 AT DIGESTIVE DISEASE WEEK 2016

Evoke Pharma Inc (Evoke Pharma) is a specialty pharmaceutical company that develops drugs to treat gastrointestinal diseases.

  • Gastrointestinal Drug
  • Healthcare
  • Pharmaceutical
  • United States
  • Evoke Pharma, Inc.
  • Official Title
  • Clinical Trial profile. 145 Trial Title

Gastrointestinal Cancer A Clinical Study to Which Anti-emetic Effect of Change of ##-HT##RA is Evaluated by Using MAT in MEC for Gastrointestinal Cancer GDCT## UMIN##, Gastrointestinal Emesis (Vomiting), Gastrointestinal Tract Cancer, Nausea Completed Ph

  • Analgesic
  • Clinical Trial
  • Gastrointestinal Drug
  • World
  • Merck & Co., Inc.
  • SCHNELL BIOPHARMA COMPLETES ISSUE OF EIGHTH UNSECURED BONDS DUE 2014 FOR US$14.5 MILLION
  • SCHNELL BIOPHARMA COMPLETES ISSUE OF NINTH UNSECURED BONDS DUE 2014 FOR US$8.8 MILLION

Its products portfolio includes antibiotics, infusions, containing amino acid, vitamin and hepatic protect infusions; gastrointestinal agents, comprising of digestives and antiulcerants.

  • Gastrointestinal Drug
  • South Korea
  • Corporate Finance
  • M&A
  • Biopharmaceuticals Inc.
  • Ironwood Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • R&D Progress

It discovers, develops and commercializes medicines for gastrointestinal disorders.

  • Gastrointestinal Drug
  • United States
  • World
  • Product Initiative
  • Ironwood Pharmaceuticals, Inc.
  • VENTURE FINANCING
  • Deal Type

Seeto has published several publications in peer-reviewed journals, including publications focused on his work in gastrointestinal research.

  • Gastrointestinal Drug
  • United States
  • Company
  • Company Operations
  • Ardelyx, Inc.
  • DIARRHEA - PIPELINE BY RXBIO INC, H1 2017
  • DIARRHEA - PIPELINE BY REDHILL BIOPHARMA LTD, H1 2017

Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • World
  • Product Initiative
  • NARONAPRIDE - DRUG PROFILE
  • DA-6886 - DRUG PROFILE

These agents also stimulate motility throughout the gastrointestinal tract.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Product Initiative
  • PARTNERSHIPS
  • ACQUISITION

Synergy Pharmaceuticals Inc (Synergy Pharma) develops therapies for gastrointestinal (GI) diseases.

  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Corporate Finance
  • Synergy Pharmaceuticals, Inc.
  • JAN 12, 2017: REDHILL BIOPHARMA PROVIDES MILESTONE UPDATE ON BEKINDA
  • JAN 12, 2017: REDHILL BIOPHARMA PROVIDES MILESTONE UPDATE ON RHB-105

IBS is one of the most common gastrointestinal disorders.

  • Biopharmaceutical
  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • RedHill Biopharma Ltd.
  • REDHILL BIOPHARMA LTD - OPPORTUNITIES
  • JAN 04, 2017: REDHILL AND CONCORDIA SIGN CO-PROMOTION AGREEMENT FOR DONNATAL DRUG PROMOTION

According to the International Foundation for Functional Gastrointestinal Disorders, IBS is the most common functional gastrointestinal disorder.

  • Biopharmaceutical
  • Gastrointestinal Drug
  • United States
  • Company Financials
  • RedHill Biopharma Ltd.
  • FEATURED NEWS & PRESS RELEASES

Gastrointestinal ulcers and gastric motility disorders are common in China and have a significant patient base.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Litigation And Patent
  • AstraZeneca PLC
  • REDHILL BIOPHARMA LTD
  • SCY-002P - DRUG PROFILE

IBS is one of the most common gastrointestinal disorders##.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Product Initiative
  • NARONAPRIDE - DRUG PROFILE
  • CEM-031 - DRUG PROFILE

This use patent allowance grants RaQualia the right to develop the acid pump antagonist to be used as a gastrointestinal function adjustment drug or a gastrointestinal motility activation drug.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Product Initiative
  • IRONWOOD PHARMA COMPLETES PRIVATE PLACEMENT OF NOTES DUE 2024 FOR US$175 MILLION
  • Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details

Synergy Pharmaceuticals Inc (Synergy Pharma) develops therapies for gastrointestinal (GI) diseases.

  • Gastrointestinal Drug
  • United States
  • Company
  • Company Financials
  • Ironwood Pharmaceuticals, Inc.
  • MAY 02, 2001: ASTRAZENECA RECEIVES SIX MONTHS' MARKET EXCLUSIVITY FOR PRILOSEC
  • OCT 20, 2000: JOINT FDA ADVISORY COMMITTEE CONFIRMS OTC PRILOSEC (OMEPRAZOLE) SAFETY AND EFFICACY

Gastrointestinal ulcers and gastric motility disorders are common in China and have a significant patient base.

  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Litigation And Patent
  • AstraZeneca PLC
  • Corporate Communications
  • Aug 30, 2016: Biomerica Announces Year End Results

It focuses on the development of products for diabetes, gastrointestinal, food intolerances and esoteric tests by utilizing enzyme immunoassay technology.

  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Demand
  • Biomerica, Inc.
  • Clinical Trials by E7 Countries: Proportion of Infectious Diarrhea to Gastrointestinal Clinical Trials
  • Clinical Trials by G7 Countries: Proportion of Infectious Diarrhea to Gastrointestinal Clinical Trials
  • Clinical Trial
  • Gastrointestinal Drug
  • World
  • Product Initiative
  • Glenmark Pharmaceuticals Ltd.
  • OCT 20, 2000: JOINT FDA ADVISORY COMMITTEE CONFIRMS OTC PRILOSEC (OMEPRAZOLE) SAFETY AND EFFICACY
  • DEC 12, 2003: ASTRAZENECA PRILOSEC PATENTS UPHELD BY FEDERAL APPEALS COURT

Gastrointestinal ulcers and gastric motility disorders are common in China and have a significant patient base.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Litigation And Patent
  • NARONAPRIDE - DRUG PROFILE
  • ELOBIXIBAT - DRUG PROFILE

These agents also stimulate motility throughout the gastrointestinal tract.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • OTC
  • United States
  • Product Initiative
  • IRRITABLE BOWEL SYNDROME - PIPELINE BY RAQUALIA PHARMA INC, H1 2017
  • IRRITABLE BOWEL SYNDROME - PIPELINE BY REDHILL BIOPHARMA LTD, H1 2017

IBS is one of the most common gastrointestinal disorders.

  • Gastrointestinal Drug
  • Therapy
  • United States
  • Product Initiative
  • Ironwood Pharmaceuticals, Inc.

It provides medicines for pain, respiratory disease, urinary incontinence, attention deficit hyperactivity disorder, gastrointestinal disorders, psychiatry, neurology, infection control and others.

  • Gastrointestinal Drug
  • Healthcare
  • Pharmaceutical
  • United States
  • Purdue Pharma L.P.
  • RENZAPRIDE - DRUG PROFILE

Gastrointestinal (GI) dysmotility is an important mechanism in functional GI disorders.

  • Diabetes
  • Gastrointestinal Drug
  • United States
  • Product Initiative
  • Evoke Pharma, Inc.

These efforts are being led by Dr Mark Pimentel, director of the gastrointestinal motility program at Cedars-Sinai Medical Center.

  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Company
  • Synthetic Biologics
  • NARONAPRIDE - DRUG PROFILE
  • RQ-00000774 - DRUG PROFILE

It discovers, develops and commercializes medicines for gastrointestinal disorders.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Product Initiative
  • RaQualia Pharma Inc.